PRAXPraxis Precision Medicines, Inc.

Two FDA applications advance as cash runway extends into 2028.

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

Praxis Precision Medicines reported its second-quarter 2026 results, posting a net loss of US$83.72 million and basic loss per share from continuing operations of US$2.87, while reaffirming its focus on central nervous system therapies. Alongside widening year-to-date losses, the company highlighted progress on key drug candidates such as ulixacaltamide and relutrigine, supported by a US$1.40 billion cash position that funds operations into 2028. With this mix of heavier losses and robust...

Moby summary of Praxis Precision Medicines, Inc.'s Q2 2026 earnings call

Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review. Chief Exe

Praxis Precision Medicines Inc (PRAX) reports strong regulatory progress for ulixacaltamide and relutrigine, while addressing the POWER1 miss and preparing for commercial launches.

Insmed stock led a biotech rally Thursday, catapulting 34% on solid second-quarter sales for its new lung disease drug, Brinsupri.

Delcath Systems announced a return to profitability after posting losses in the past two quarters, while Praxis’ second-quarter loss came in narrower than Wall Street had expected

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 affordable biotech stocks to buy right now. On July 7, Praxis Precision Medicines Inc. (NASDAQ:PRAX) and Remagine Labs disclosed a research partnership and license agreement to design an iontophoretic transdermal patch for the delivery of ulixacaltamide. Ulixacaltamide is a strongly targeted T-type calcium channel inhibitor […]